Logo

BOWN

Bowen Acquisition Corp

BOWN

Bowen Acquisition Corp • NASDAQ
$9.19 ▼ -0.11% (-0.01)
Market Cap $27.52 M
52w High $19.77
52w Low $2.71
Dividend Yield 0%
P/E -41.77
Volume 2.83K
Outstanding Shares 2.99M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $76.828K ▼ $750.303K ▲ 0% $0.34 ▲ $-76.828K ▲
Q1-2025 $0 $134.736K ▼ $-2.04M ▼ 0% $-0.54 ▼ $-1.935M ▼
Q4-2024 $0 $244.109K ▲ $535.378K ▼ 0% $0.067 ▼ $3.441M ▲
Q3-2024 $0 $127.429K ▲ $825.358K ▲ 0% $0.09 ▲ $429 ▼
Q2-2024 $0 $125.096K $816.754K 0% $0.089 $941.85K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $17.556K ▼ $8.515M ▼ $2.138M ▼ $6.377M ▼
Q1-2025 $29.806K ▼ $9.62M ▼ $2.848M ▲ $6.772M ▼
Q4-2024 $103.774K ▼ $76.048M ▲ $1.053M ▼ $74.995M ▲
Q3-2024 $271.847K ▼ $74.534M ▲ $74.522M ▲ $12.879K ▼
Q2-2024 $272.63K $73.645M $219.73K $73.425M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $750.306K ▲ $-12.25K ▲ $1.145M ▼ $-1.145M ▲ $-12.25K ▲ $-12.25K ▲
Q1-2025 $-2.04M ▼ $-73.968K ▲ $66.519M ▲ $-66.519M ▼ $-73.968K ▲ $-73.968K ▲
Q4-2024 $535.378K ▼ $-168.073K ▼ $-690K ▼ $690K ▲ $-168.073K ▼ $-168.073K ▼
Q3-2024 $825.358K ▲ $-783 ▲ $0 $0 $-783 ▲ $-783 ▲
Q2-2024 $816.754K $-63.329K $0 $0 $-63.329K $-63.329K

Five-Year Company Overview

Income Statement

Income Statement Bowen is still a blank‑check company, so its income statement is mostly an accounting formality rather than a picture of a real operating business. It shows no meaningful revenue, no operating activity, and a small amount of reported profit per share that likely comes from interest and SPAC-related accounting, not from selling products or services. Until the merger closes and Qianzhi BioTech’s results are consolidated, the current income statement tells you almost nothing about the future underlying business performance.

Balance Sheet

Balance Sheet The balance sheet is very light, as you’d expect for a SPAC. It shows modest assets and equity, with essentially no reported debt and no traditional operating assets. In practical terms, Bowen is just a financial shell set up to hold capital for a deal. The real balance sheet risk and strength will come later, once Qianzhi BioTech’s assets, liabilities, and any merger-related debt are added in. For now, financial leverage looks low, but the base of assets is also very small and entirely deal‑dependent.

Cash Flow

Cash Flow Cash flow is essentially flat and inactive, again typical of a SPAC before a merger. There is no operating cash coming in from customers and no real investment in facilities or equipment. Any meaningful cash flows will begin only after the business combination, when Qianzhi BioTech’s day‑to‑day operations, investments, and potential funding needs start to show up in the combined company’s cash flow statement.

Competitive Edge

Competitive Edge As of today, Bowen has no operating business, so it has no true market position of its own. The future competitive picture depends on Qianzhi BioTech. That business aims to carve out a niche in health and wellness using ozone‑based and plant‑based products, focusing on intimate care, skincare, and disinfectants. Its potential edge comes from specialized technology and an early presence in this niche space, but it will still be competing against many established personal care and hygiene brands, along with the usual regulatory, safety, and marketing challenges in health‑related products.

Innovation and R&D

Innovation and R&D The main innovation story lives inside Qianzhi BioTech, not Bowen itself. Qianzhi claims a proprietary way to stabilize ozone at room temperature and combine it with plant‑based ingredients for consumer health products. This could be a meaningful differentiator if the technology is truly hard to copy, well‑protected by intellectual property, and backed by solid clinical evidence. However, public detail on research spending, pipeline depth, and scientific validation is limited, so there is uncertainty around how durable this innovation edge will be and how easily it can be scaled or expanded into new product categories or geographies.

Summary

Bowen Acquisition Corp today is a financial shell with no operations, minimal assets beyond its SPAC structure, and no real cash‑generating activity. Its reported financials are clean but not very informative about future performance. The investment story really hinges on the planned merger with Shenzhen Qianzhi BioTechnology, a niche health and wellness company built around ozone‑based and plant‑derived products. That target brings a specialized technology platform and early‑mover positioning in a small but growing segment, along with typical risks around regulation, scientific proof, branding, and international expansion. Until the merger closes and Qianzhi’s full financials are available, Bowen’s current reports should be viewed mainly as a shell framework rather than a reflection of a mature operating business.